Crinecerfont is a corticotropin-releasing factor type 1 receptor antagonist used to reduce replacement glucocorticoid requirements in patients with congenital adrenal hyperplasia. Patients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocorticotropic hormone (ACTH) from the pituitary.
- Mechanism
- Curator reviewed · 5 references
Crinecerfont exerts its therapeutics effects via selective antagonism of corticotropin releasing factor (CRF) type 1 receptor, which is abundant in the pituitary gland. It blocks the binding of CRF to CRF type 1 receptors in the pituitary gland, which inhibits the secretion of adrenocorticotropic hormone (ACTH) from the pituitary. This reduction in ACTH leads to decreased adrenal androgen production and lower levels of steroid precursors, such as 17OH-progesterone.
- Primary indication
- Crinecerfont is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients ≥4 years of age with classic congenital adrenal hyperplasia (CAH).Curator reviewed · 1 structured indication
- Formula / weight
- C27H28ClFN2OS · 483.04 g/mol (avg)
- First approval
- United States, 2024
- Code names
- 06-RORI · NBI-74788 · SSR-125543
- Brand names
Resolves to
IEAKXXNRGSLYTQ-DEOSSOPVSA-NSMILESCOC1=CC(Cl)=C(C=C1C)C1=C(C)SC(=N1)N(CC#C)[C@@H](CC1CC1)C1=CC=C(C)C(F)=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Crinecerfont, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account